List of Vimpat drug patents
Vimpat is owned by Ucb Inc.
Vimpat contains Lacosamide.
Vimpat has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Vimpat are:
- USRE38551
Vimpat was authorised for market use on 28 October, 2008.
Vimpat is available in solution;intravenous dosage forms.
Vimpat can be used as method of treating partial onset seizures in patients 4 years of age and older; method of treating, as initial loading dose for monotherapy or adjunctive therapy, partial onset-seizures in a patient with epilepsy aged 17 years or older; method of use of treating, as an initial loading dose for monotherapy or adjunctive therapy in partial onset seizure patients with epilepsy aged 17 years or older; method of use for treatment of partial-onset seizures in patients 4 years of age and older; method of use as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
The generics of Vimpat are possible to be released after 14 October, 2024.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE38551 | UCB INC | Anticonvulsant enantiomeric amino acid derivatives |
Mar, 2022
(1 year, 5 days ago) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Nov 16, 2023 |
| New Patient Population (NPP) | Oct 14, 2024 |
Drugs and Companies using LACOSAMIDE ingredient
Market Authorisation Date: 28 October, 2008
Treatment: Method of treating partial onset seizures in patients 4 years of age and older; Method of treating, as initial loading dose for monotherapy or adjunctive therapy, partial onset-seizures in a patient with epilepsy aged 17 years or older; Method of use of treating, as an initial loading dose for monotherapy or adjunctive therapy in partial onset seizure patients with epilepsy aged 17 years or older; Method of use for treatment of partial-onset seizures in patients 4 years of age and older; Method of use as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older
Dosage: SOLUTION;INTRAVENOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic